| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pancreatic Neoplasms | 50 | 2024 | 540 | 11.660 |
Why?
|
| Mucin-1 | 15 | 2024 | 36 | 4.180 |
Why?
|
| Glucose | 20 | 2022 | 204 | 3.440 |
Why?
|
| Carcinoma, Pancreatic Ductal | 14 | 2022 | 138 | 3.160 |
Why?
|
| Cell Line, Tumor | 45 | 2024 | 1319 | 2.840 |
Why?
|
| Gene Expression Regulation, Neoplastic | 19 | 2021 | 465 | 2.550 |
Why?
|
| Cachexia | 5 | 2020 | 53 | 2.490 |
Why?
|
| Signal Transduction | 31 | 2024 | 1435 | 2.170 |
Why?
|
| Metabolomics | 8 | 2024 | 85 | 2.150 |
Why?
|
| Energy Metabolism | 8 | 2024 | 200 | 2.110 |
Why?
|
| Glycolysis | 14 | 2021 | 85 | 2.110 |
Why?
|
| Neoplasms | 11 | 2023 | 808 | 2.050 |
Why?
|
| Humans | 135 | 2024 | 28094 | 2.040 |
Why?
|
| Macrophages | 7 | 2021 | 295 | 2.010 |
Why?
|
| Mice | 58 | 2024 | 4650 | 1.940 |
Why?
|
| Metabolome | 6 | 2020 | 68 | 1.900 |
Why?
|
| Radiation-Protective Agents | 10 | 2013 | 22 | 1.820 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 5 | 2018 | 60 | 1.750 |
Why?
|
| Animals | 71 | 2024 | 10415 | 1.730 |
Why?
|
| Deoxycytidine | 6 | 2021 | 65 | 1.670 |
Why?
|
| Glutamine | 6 | 2019 | 32 | 1.650 |
Why?
|
| Xenograft Model Antitumor Assays | 10 | 2021 | 269 | 1.620 |
Why?
|
| Pancreas | 7 | 2024 | 61 | 1.550 |
Why?
|
| Adenocarcinoma | 8 | 2021 | 298 | 1.480 |
Why?
|
| Tumor Microenvironment | 8 | 2023 | 177 | 1.360 |
Why?
|
| Carrier Proteins | 9 | 2022 | 252 | 1.340 |
Why?
|
| Endoplasmic Reticulum Stress | 3 | 2020 | 39 | 1.240 |
Why?
|
| Cell Proliferation | 19 | 2021 | 806 | 1.170 |
Why?
|
| Cell Hypoxia | 7 | 2021 | 35 | 1.040 |
Why?
|
| Oxidoreductases Acting on CH-CH Group Donors | 2 | 2024 | 10 | 1.040 |
Why?
|
| Cell Culture Techniques | 4 | 2019 | 116 | 0.990 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 4 | 2022 | 63 | 0.980 |
Why?
|
| Mice, Nude | 16 | 2021 | 331 | 0.960 |
Why?
|
| Lung Neoplasms | 7 | 2022 | 356 | 0.950 |
Why?
|
| Podophyllum | 3 | 2009 | 3 | 0.950 |
Why?
|
| Sirtuins | 2 | 2022 | 17 | 0.930 |
Why?
|
| Lafora Disease | 4 | 2013 | 5 | 0.920 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2024 | 409 | 0.910 |
Why?
|
| Neoplasm Proteins | 3 | 2023 | 123 | 0.890 |
Why?
|
| Drug Resistance, Neoplasm | 4 | 2018 | 167 | 0.890 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2015 | 82 | 0.880 |
Why?
|
| Antigen Presentation | 1 | 2024 | 78 | 0.870 |
Why?
|
| Antimetabolites, Antineoplastic | 4 | 2018 | 48 | 0.860 |
Why?
|
| Endosonography | 3 | 2009 | 37 | 0.850 |
Why?
|
| Muscle, Skeletal | 4 | 2020 | 634 | 0.840 |
Why?
|
| Esophageal Neoplasms | 1 | 2023 | 32 | 0.820 |
Why?
|
| MAP Kinase Signaling System | 2 | 2020 | 95 | 0.800 |
Why?
|
| Proto-Oncogene Proteins c-myc | 3 | 2022 | 44 | 0.790 |
Why?
|
| Membrane Proteins | 3 | 2019 | 484 | 0.790 |
Why?
|
| Whole-Body Irradiation | 6 | 2013 | 40 | 0.770 |
Why?
|
| Myeloid-Derived Suppressor Cells | 1 | 2022 | 6 | 0.770 |
Why?
|
| Liver Neoplasms | 3 | 2009 | 165 | 0.760 |
Why?
|
| Aspartate Aminotransferase, Cytoplasmic | 2 | 2021 | 6 | 0.740 |
Why?
|
| Gene Expression Profiling | 5 | 2018 | 453 | 0.730 |
Why?
|
| Female | 44 | 2022 | 15153 | 0.730 |
Why?
|
| Sirtuin 1 | 2 | 2022 | 41 | 0.720 |
Why?
|
| Cellular Reprogramming | 2 | 2020 | 10 | 0.720 |
Why?
|
| Plant Extracts | 3 | 2012 | 62 | 0.720 |
Why?
|
| Mitochondria | 7 | 2022 | 369 | 0.710 |
Why?
|
| NADPH Oxidase 4 | 1 | 2020 | 8 | 0.690 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2020 | 33 | 0.690 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 5 | 2013 | 18 | 0.680 |
Why?
|
| alpha-Tocopherol | 4 | 2013 | 5 | 0.680 |
Why?
|
| Muscle Proteins | 1 | 2020 | 56 | 0.670 |
Why?
|
| Proteomics | 2 | 2021 | 181 | 0.670 |
Why?
|
| Cytidine Deaminase | 1 | 2020 | 8 | 0.670 |
Why?
|
| Mucins | 4 | 2008 | 24 | 0.670 |
Why?
|
| Lactic Acid | 2 | 2018 | 92 | 0.670 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2009 | 103 | 0.670 |
Why?
|
| Autophagy | 3 | 2019 | 73 | 0.660 |
Why?
|
| Male | 46 | 2022 | 13489 | 0.660 |
Why?
|
| Radiation Tolerance | 2 | 2017 | 28 | 0.650 |
Why?
|
| Intracranial Aneurysm | 5 | 2013 | 58 | 0.650 |
Why?
|
| Reactive Oxygen Species | 5 | 2020 | 285 | 0.650 |
Why?
|
| Spinal Neoplasms | 2 | 2011 | 39 | 0.640 |
Why?
|
| Cell Membrane | 3 | 2020 | 259 | 0.610 |
Why?
|
| Tomography, X-Ray Computed | 7 | 2013 | 474 | 0.600 |
Why?
|
| DNA Damage | 2 | 2017 | 151 | 0.580 |
Why?
|
| Arginase | 1 | 2018 | 6 | 0.580 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2018 | 40 | 0.570 |
Why?
|
| Sequence Analysis, RNA | 1 | 2018 | 58 | 0.560 |
Why?
|
| Protein Tyrosine Phosphatases, Non-Receptor | 3 | 2013 | 20 | 0.560 |
Why?
|
| Cell Survival | 8 | 2020 | 409 | 0.560 |
Why?
|
| Acidosis | 1 | 2017 | 11 | 0.550 |
Why?
|
| Cell Line | 9 | 2022 | 696 | 0.550 |
Why?
|
| Lipids | 2 | 2017 | 208 | 0.540 |
Why?
|
| Muscle Fibers, Skeletal | 4 | 2020 | 50 | 0.530 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2017 | 36 | 0.530 |
Why?
|
| Radiation Injuries | 5 | 2013 | 52 | 0.530 |
Why?
|
| Mice, Inbred C57BL | 8 | 2024 | 1574 | 0.530 |
Why?
|
| Apoptosis | 7 | 2019 | 775 | 0.530 |
Why?
|
| Gene Knockdown Techniques | 4 | 2018 | 134 | 0.520 |
Why?
|
| Stress, Physiological | 1 | 2017 | 96 | 0.520 |
Why?
|
| RNA Interference | 7 | 2020 | 137 | 0.510 |
Why?
|
| Microfilament Proteins | 3 | 2021 | 31 | 0.510 |
Why?
|
| Craniopharyngioma | 2 | 2014 | 14 | 0.510 |
Why?
|
| Silymarin | 1 | 2015 | 6 | 0.500 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2007 | 131 | 0.500 |
Why?
|
| Magnetic Resonance Imaging | 12 | 2013 | 819 | 0.500 |
Why?
|
| Enzyme Inhibitors | 3 | 2024 | 250 | 0.490 |
Why?
|
| Pituitary Neoplasms | 2 | 2014 | 48 | 0.490 |
Why?
|
| CA-125 Antigen | 1 | 2015 | 19 | 0.490 |
Why?
|
| Dura Mater | 2 | 2013 | 11 | 0.490 |
Why?
|
| Glycogen | 2 | 2013 | 23 | 0.480 |
Why?
|
| Pyrimidines | 3 | 2022 | 125 | 0.470 |
Why?
|
| Tocopherols | 2 | 2011 | 3 | 0.470 |
Why?
|
| Cell Cycle Proteins | 4 | 2015 | 187 | 0.460 |
Why?
|
| HIV-1 | 2 | 2011 | 58 | 0.450 |
Why?
|
| Gastrointestinal Diseases | 2 | 2012 | 54 | 0.450 |
Why?
|
| Spinal Cord Diseases | 2 | 2011 | 31 | 0.440 |
Why?
|
| Dual-Specificity Phosphatases | 1 | 2013 | 6 | 0.430 |
Why?
|
| Immediate-Early Proteins | 1 | 2013 | 15 | 0.430 |
Why?
|
| Biopsy, Fine-Needle | 3 | 2009 | 24 | 0.410 |
Why?
|
| Rhizome | 2 | 2009 | 3 | 0.400 |
Why?
|
| Chromatography, Liquid | 3 | 2018 | 76 | 0.400 |
Why?
|
| Neuroma, Acoustic | 1 | 2012 | 23 | 0.390 |
Why?
|
| Lipid Bilayers | 1 | 2012 | 15 | 0.390 |
Why?
|
| Mangifera | 1 | 2012 | 1 | 0.390 |
Why?
|
| Transcription Factors | 6 | 2020 | 520 | 0.390 |
Why?
|
| Radiation Injuries, Experimental | 2 | 2011 | 31 | 0.390 |
Why?
|
| Osteophyte | 1 | 2011 | 1 | 0.380 |
Why?
|
| Mechanical Phenomena | 1 | 2012 | 21 | 0.380 |
Why?
|
| Mutation | 7 | 2021 | 845 | 0.380 |
Why?
|
| Glucose Transport Proteins, Facilitative | 1 | 2011 | 4 | 0.380 |
Why?
|
| Tandem Mass Spectrometry | 3 | 2018 | 113 | 0.380 |
Why?
|
| Adenosine Triphosphate | 3 | 2019 | 118 | 0.380 |
Why?
|
| Skull Fracture, Depressed | 1 | 2011 | 1 | 0.380 |
Why?
|
| Gene Products, nef | 1 | 2011 | 1 | 0.380 |
Why?
|
| Fruit | 1 | 2012 | 39 | 0.380 |
Why?
|
| Biopolymers | 1 | 2011 | 15 | 0.380 |
Why?
|
| Cholesterol | 3 | 2023 | 201 | 0.370 |
Why?
|
| Neural Tube Defects | 1 | 2011 | 20 | 0.370 |
Why?
|
| Craniocerebral Trauma | 1 | 2011 | 27 | 0.370 |
Why?
|
| MicroRNAs | 2 | 2012 | 301 | 0.370 |
Why?
|
| Gastrointestinal Tract | 1 | 2011 | 35 | 0.360 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2017 | 105 | 0.360 |
Why?
|
| Neoplasm Metastasis | 5 | 2021 | 162 | 0.360 |
Why?
|
| Nanocapsules | 1 | 2011 | 4 | 0.360 |
Why?
|
| Leishmania | 1 | 2011 | 6 | 0.360 |
Why?
|
| Hemangioma | 1 | 2011 | 8 | 0.360 |
Why?
|
| Amphotericin B | 1 | 2011 | 19 | 0.350 |
Why?
|
| Cell Nucleus | 2 | 2008 | 138 | 0.350 |
Why?
|
| Dose-Response Relationship, Drug | 7 | 2015 | 607 | 0.350 |
Why?
|
| Embolization, Therapeutic | 1 | 2011 | 47 | 0.350 |
Why?
|
| Phosphorylation | 7 | 2015 | 578 | 0.340 |
Why?
|
| Culture Media, Conditioned | 3 | 2020 | 31 | 0.340 |
Why?
|
| Transfection | 5 | 2021 | 318 | 0.340 |
Why?
|
| Athletic Injuries | 1 | 2011 | 120 | 0.340 |
Why?
|
| Pentose Phosphate Pathway | 3 | 2017 | 11 | 0.340 |
Why?
|
| Actin Cytoskeleton | 2 | 2020 | 24 | 0.330 |
Why?
|
| Time Factors | 8 | 2020 | 1591 | 0.330 |
Why?
|
| Neoplasm Transplantation | 4 | 2018 | 90 | 0.330 |
Why?
|
| Antigens, Neoplasm | 2 | 2007 | 56 | 0.330 |
Why?
|
| Disease Progression | 3 | 2021 | 473 | 0.330 |
Why?
|
| Ethanol | 1 | 2011 | 123 | 0.330 |
Why?
|
| Spinal Cord | 1 | 2011 | 209 | 0.330 |
Why?
|
| Tumor Burden | 3 | 2021 | 110 | 0.320 |
Why?
|
| Benzothiazoles | 1 | 2009 | 5 | 0.320 |
Why?
|
| Toluene | 1 | 2009 | 11 | 0.320 |
Why?
|
| Precision Medicine | 2 | 2021 | 76 | 0.320 |
Why?
|
| Digestive System Neoplasms | 1 | 2009 | 5 | 0.320 |
Why?
|
| Middle Aged | 20 | 2021 | 7137 | 0.320 |
Why?
|
| Oxidation-Reduction | 3 | 2020 | 365 | 0.320 |
Why?
|
| Mice, Knockout | 5 | 2021 | 848 | 0.320 |
Why?
|
| Disease Models, Animal | 6 | 2020 | 1459 | 0.320 |
Why?
|
| Quadriplegia | 1 | 2009 | 4 | 0.310 |
Why?
|
| Tarlov Cysts | 1 | 2009 | 2 | 0.310 |
Why?
|
| N-Acetylglucosaminyltransferases | 2 | 2019 | 16 | 0.310 |
Why?
|
| Adolescent | 12 | 2021 | 3121 | 0.310 |
Why?
|
| Infertility, Male | 1 | 2009 | 23 | 0.310 |
Why?
|
| Glioblastoma | 2 | 2013 | 105 | 0.310 |
Why?
|
| Glucose Transporter Type 1 | 3 | 2019 | 15 | 0.310 |
Why?
|
| Receptors, Growth Factor | 1 | 2008 | 7 | 0.300 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2008 | 6 | 0.300 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2008 | 16 | 0.300 |
Why?
|
| Tumor Cells, Cultured | 5 | 2021 | 315 | 0.300 |
Why?
|
| Picrorhiza | 1 | 2008 | 1 | 0.300 |
Why?
|
| Drugs, Chinese Herbal | 1 | 2008 | 2 | 0.300 |
Why?
|
| Gamma Rays | 5 | 2013 | 27 | 0.300 |
Why?
|
| Real-Time Polymerase Chain Reaction | 3 | 2018 | 133 | 0.300 |
Why?
|
| Adult | 19 | 2021 | 7739 | 0.290 |
Why?
|
| HEK293 Cells | 5 | 2020 | 187 | 0.290 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2008 | 94 | 0.290 |
Why?
|
| STAT3 Transcription Factor | 2 | 2020 | 97 | 0.280 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2008 | 140 | 0.280 |
Why?
|
| Cell Movement | 5 | 2020 | 373 | 0.280 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2007 | 21 | 0.270 |
Why?
|
| Neoplasm Invasiveness | 6 | 2015 | 190 | 0.270 |
Why?
|
| Cell Count | 2 | 2018 | 86 | 0.270 |
Why?
|
| Cell Transformation, Neoplastic | 3 | 2020 | 120 | 0.270 |
Why?
|
| Hypertension | 1 | 2010 | 308 | 0.270 |
Why?
|
| Aged | 14 | 2017 | 5400 | 0.270 |
Why?
|
| Molecular Targeted Therapy | 2 | 2019 | 135 | 0.270 |
Why?
|
| Rifampin | 1 | 2006 | 7 | 0.270 |
Why?
|
| Pruritus | 1 | 2006 | 8 | 0.260 |
Why?
|
| Carcinoma, Small Cell | 1 | 2006 | 15 | 0.260 |
Why?
|
| Mice, SCID | 3 | 2021 | 61 | 0.260 |
Why?
|
| Cholestasis | 1 | 2006 | 11 | 0.260 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2019 | 163 | 0.260 |
Why?
|
| Antioxidants | 3 | 2015 | 223 | 0.250 |
Why?
|
| Algorithms | 5 | 2013 | 430 | 0.250 |
Why?
|
| Smoking | 1 | 2010 | 473 | 0.250 |
Why?
|
| Calcium Channels | 2 | 2022 | 33 | 0.240 |
Why?
|
| Immunity, Innate | 4 | 2022 | 226 | 0.240 |
Why?
|
| Mice, Transgenic | 7 | 2022 | 507 | 0.230 |
Why?
|
| Quinaldines | 1 | 2024 | 5 | 0.230 |
Why?
|
| Quinoxalines | 1 | 2024 | 17 | 0.230 |
Why?
|
| Amino Acid Sequence | 4 | 2014 | 689 | 0.230 |
Why?
|
| Survival Analysis | 5 | 2021 | 288 | 0.230 |
Why?
|
| Biphenyl Compounds | 1 | 2024 | 22 | 0.230 |
Why?
|
| Young Adult | 10 | 2021 | 2732 | 0.220 |
Why?
|
| Survival Rate | 4 | 2017 | 430 | 0.220 |
Why?
|
| Mice, Inbred NOD | 2 | 2021 | 49 | 0.220 |
Why?
|
| Melanoma, Experimental | 1 | 2024 | 31 | 0.220 |
Why?
|
| Polyamines | 1 | 2024 | 13 | 0.220 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2018 | 163 | 0.220 |
Why?
|
| Carcinogenesis | 2 | 2022 | 81 | 0.220 |
Why?
|
| COS Cells | 3 | 2013 | 49 | 0.220 |
Why?
|
| Oxidative Phosphorylation | 3 | 2020 | 29 | 0.220 |
Why?
|
| Molecular Sequence Data | 4 | 2014 | 1051 | 0.220 |
Why?
|
| Histone Deacetylases | 2 | 2022 | 26 | 0.220 |
Why?
|
| Acetyltransferases | 1 | 2024 | 36 | 0.220 |
Why?
|
| Inflammation | 3 | 2020 | 636 | 0.220 |
Why?
|
| Prognosis | 4 | 2017 | 802 | 0.220 |
Why?
|
| Treatment Outcome | 9 | 2013 | 2377 | 0.210 |
Why?
|
| Anoctamin-1 | 1 | 2023 | 3 | 0.210 |
Why?
|
| Lipid Metabolism | 2 | 2022 | 133 | 0.210 |
Why?
|
| Unfolded Protein Response | 2 | 2020 | 25 | 0.210 |
Why?
|
| Actins | 2 | 2020 | 96 | 0.210 |
Why?
|
| Protein Stability | 2 | 2020 | 43 | 0.210 |
Why?
|
| Nucleotides | 1 | 2023 | 20 | 0.210 |
Why?
|
| Fibrosis | 4 | 2022 | 133 | 0.200 |
Why?
|
| Pyrimidine Nucleotides | 1 | 2022 | 4 | 0.200 |
Why?
|
| RNA, Small Interfering | 5 | 2020 | 198 | 0.200 |
Why?
|
| Teratoma | 2 | 2013 | 17 | 0.200 |
Why?
|
| Equilibrative Nucleoside Transporter 1 | 1 | 2022 | 15 | 0.200 |
Why?
|
| Sirtuin 3 | 1 | 2022 | 18 | 0.200 |
Why?
|
| Enzyme Activation | 2 | 2021 | 267 | 0.200 |
Why?
|
| Thalamus | 2 | 2013 | 26 | 0.200 |
Why?
|
| Melanins | 1 | 2022 | 6 | 0.200 |
Why?
|
| Dengue | 2 | 2013 | 5 | 0.200 |
Why?
|
| Carcinogens | 1 | 2022 | 39 | 0.200 |
Why?
|
| Biological Transport | 2 | 2013 | 122 | 0.200 |
Why?
|
| G-Quadruplexes | 1 | 2022 | 1 | 0.200 |
Why?
|
| DNA-(Apurinic or Apyrimidinic Site) Lyase | 1 | 2022 | 3 | 0.200 |
Why?
|
| Skin Pigmentation | 1 | 2022 | 10 | 0.200 |
Why?
|
| Brain Injuries | 2 | 2013 | 49 | 0.190 |
Why?
|
| Ventriculoperitoneal Shunt | 2 | 2013 | 26 | 0.190 |
Why?
|
| Inhibin-beta Subunits | 1 | 2022 | 3 | 0.190 |
Why?
|
| Activins | 1 | 2022 | 4 | 0.190 |
Why?
|
| Radiation Exposure | 1 | 2022 | 17 | 0.190 |
Why?
|
| Acute Radiation Syndrome | 2 | 2012 | 3 | 0.190 |
Why?
|
| Adipocytes, White | 1 | 2022 | 10 | 0.190 |
Why?
|
| Metalloporphyrins | 1 | 2022 | 18 | 0.190 |
Why?
|
| Intra-Abdominal Fat | 1 | 2022 | 21 | 0.190 |
Why?
|
| Pyrvinium Compounds | 1 | 2021 | 1 | 0.190 |
Why?
|
| Anthelmintics | 1 | 2021 | 4 | 0.190 |
Why?
|
| Immunoglobulin E | 1 | 2021 | 19 | 0.190 |
Why?
|
| Enzyme Activators | 1 | 2021 | 9 | 0.190 |
Why?
|
| Probiotics | 1 | 2021 | 18 | 0.180 |
Why?
|
| Phosphofructokinase-2 | 1 | 2021 | 11 | 0.180 |
Why?
|
| Immune Evasion | 1 | 2021 | 8 | 0.180 |
Why?
|
| Child | 9 | 2014 | 2242 | 0.180 |
Why?
|
| NF-kappa B | 2 | 2020 | 191 | 0.180 |
Why?
|
| Prostatic Neoplasms | 2 | 2022 | 277 | 0.180 |
Why?
|
| Aged, 80 and over | 7 | 2017 | 2021 | 0.180 |
Why?
|
| Hyperglycemia | 1 | 2022 | 78 | 0.180 |
Why?
|
| Adiposity | 1 | 2022 | 94 | 0.180 |
Why?
|
| Cervical Vertebrae | 2 | 2013 | 114 | 0.180 |
Why?
|
| Gastroesophageal Reflux | 1 | 2021 | 84 | 0.180 |
Why?
|
| Nuclear Proteins | 2 | 2015 | 247 | 0.180 |
Why?
|
| Necrosis | 2 | 2019 | 85 | 0.180 |
Why?
|
| Atherosclerosis | 1 | 2022 | 96 | 0.180 |
Why?
|
| Oxaloacetic Acid | 2 | 2017 | 8 | 0.170 |
Why?
|
| Anthracenes | 1 | 2020 | 7 | 0.170 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2021 | 49 | 0.170 |
Why?
|
| Mentoring | 1 | 2020 | 11 | 0.170 |
Why?
|
| Wasting Syndrome | 1 | 2020 | 7 | 0.170 |
Why?
|
| Cultural Diversity | 1 | 2020 | 19 | 0.170 |
Why?
|
| Prostaglandin D2 | 1 | 2020 | 6 | 0.170 |
Why?
|
| Promoter Regions, Genetic | 3 | 2012 | 343 | 0.170 |
Why?
|
| Infant | 6 | 2013 | 1004 | 0.170 |
Why?
|
| Tumor Escape | 1 | 2020 | 11 | 0.170 |
Why?
|
| Adipose Tissue | 2 | 2020 | 183 | 0.170 |
Why?
|
| Calcium Signaling | 1 | 2021 | 72 | 0.170 |
Why?
|
| Forkhead Transcription Factors | 1 | 2020 | 35 | 0.170 |
Why?
|
| Muscular Atrophy | 1 | 2020 | 31 | 0.170 |
Why?
|
| Biomechanical Phenomena | 2 | 2012 | 180 | 0.170 |
Why?
|
| Listeria monocytogenes | 1 | 2021 | 59 | 0.170 |
Why?
|
| Phagocytosis | 1 | 2021 | 80 | 0.170 |
Why?
|
| Research Personnel | 1 | 2020 | 39 | 0.170 |
Why?
|
| Oligomycins | 1 | 2020 | 1 | 0.170 |
Why?
|
| Implants, Experimental | 1 | 2020 | 3 | 0.170 |
Why?
|
| Adipocytes | 2 | 2019 | 56 | 0.170 |
Why?
|
| Golgi Apparatus | 1 | 2020 | 26 | 0.170 |
Why?
|
| Cerebrovascular Circulation | 3 | 2010 | 220 | 0.170 |
Why?
|
| Vesicular Transport Proteins | 1 | 2020 | 34 | 0.170 |
Why?
|
| Cell Differentiation | 2 | 2021 | 407 | 0.170 |
Why?
|
| Sensitivity and Specificity | 4 | 2009 | 521 | 0.160 |
Why?
|
| Models, Cardiovascular | 2 | 2010 | 47 | 0.160 |
Why?
|
| Gene Regulatory Networks | 2 | 2018 | 77 | 0.160 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2019 | 27 | 0.160 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2021 | 123 | 0.160 |
Why?
|
| Endoplasmic Reticulum | 1 | 2020 | 80 | 0.160 |
Why?
|
| SOXB1 Transcription Factors | 1 | 2019 | 3 | 0.160 |
Why?
|
| Electron Transport Complex I | 1 | 2019 | 13 | 0.160 |
Why?
|
| ErbB Receptors | 2 | 2020 | 100 | 0.160 |
Why?
|
| Diabetes Mellitus | 1 | 2022 | 215 | 0.160 |
Why?
|
| Poloxamer | 1 | 2019 | 6 | 0.160 |
Why?
|
| Spleen | 4 | 2020 | 112 | 0.160 |
Why?
|
| Brain Neoplasms | 2 | 2013 | 301 | 0.160 |
Why?
|
| Biomedical Research | 1 | 2020 | 97 | 0.160 |
Why?
|
| Positron-Emission Tomography | 3 | 2017 | 99 | 0.160 |
Why?
|
| Biomarkers, Tumor | 2 | 2013 | 404 | 0.160 |
Why?
|
| Staphylococcus aureus | 1 | 2020 | 117 | 0.160 |
Why?
|
| Proteasome Inhibitors | 1 | 2019 | 26 | 0.160 |
Why?
|
| Chloroquine | 1 | 2019 | 9 | 0.160 |
Why?
|
| Interleukin-6 | 3 | 2015 | 193 | 0.160 |
Why?
|
| Rotarod Performance Test | 1 | 2019 | 2 | 0.160 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 2017 | 267 | 0.160 |
Why?
|
| Rhabdoviridae Infections | 1 | 2018 | 2 | 0.160 |
Why?
|
| Decompression, Surgical | 2 | 2011 | 76 | 0.160 |
Why?
|
| Homeostasis | 1 | 2020 | 118 | 0.160 |
Why?
|
| Vesicular stomatitis Indiana virus | 1 | 2018 | 8 | 0.160 |
Why?
|
| Staphylococcal Infections | 1 | 2020 | 83 | 0.160 |
Why?
|
| Prospective Studies | 5 | 2012 | 1248 | 0.150 |
Why?
|
| Multiple Myeloma | 1 | 2019 | 38 | 0.150 |
Why?
|
| 3T3-L1 Cells | 1 | 2019 | 29 | 0.150 |
Why?
|
| Superoxides | 1 | 2019 | 62 | 0.150 |
Why?
|
| Receptor-Interacting Protein Serine-Threonine Kinases | 1 | 2019 | 22 | 0.150 |
Why?
|
| Laminectomy | 2 | 2009 | 30 | 0.150 |
Why?
|
| Monocytes | 1 | 2020 | 135 | 0.150 |
Why?
|
| Prosthesis Implantation | 2 | 2010 | 26 | 0.150 |
Why?
|
| RNA, Messenger | 3 | 2022 | 659 | 0.150 |
Why?
|
| Biofilms | 1 | 2020 | 121 | 0.150 |
Why?
|
| Drug Monitoring | 1 | 2018 | 36 | 0.150 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2018 | 20 | 0.150 |
Why?
|
| Absorptiometry, Photon | 1 | 2019 | 100 | 0.150 |
Why?
|
| Immunotherapy | 1 | 2020 | 160 | 0.150 |
Why?
|
| ELAV-Like Protein 1 | 1 | 2018 | 30 | 0.150 |
Why?
|
| Cytokines | 3 | 2020 | 447 | 0.150 |
Why?
|
| Neoplastic Stem Cells | 1 | 2019 | 141 | 0.150 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2019 | 97 | 0.150 |
Why?
|
| U937 Cells | 1 | 2018 | 8 | 0.150 |
Why?
|
| Dichloroacetic Acid | 1 | 2018 | 1 | 0.150 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2019 | 106 | 0.150 |
Why?
|
| Ubiquitin-Protein Ligases | 3 | 2013 | 70 | 0.150 |
Why?
|
| Oxidative Stress | 3 | 2019 | 668 | 0.150 |
Why?
|
| Pulmonary Fibrosis | 1 | 2018 | 15 | 0.150 |
Why?
|
| Predictive Value of Tests | 2 | 2010 | 474 | 0.150 |
Why?
|
| Carboxymethylcellulose Sodium | 1 | 2017 | 3 | 0.140 |
Why?
|
| Cell Polarity | 1 | 2018 | 22 | 0.140 |
Why?
|
| Gene Library | 1 | 2018 | 45 | 0.140 |
Why?
|
| Poly I-C | 1 | 2017 | 10 | 0.140 |
Why?
|
| Cell Separation | 1 | 2018 | 55 | 0.140 |
Why?
|
| Oxygen Consumption | 1 | 2019 | 181 | 0.140 |
Why?
|
| Polylysine | 1 | 2017 | 14 | 0.140 |
Why?
|
| NADP | 1 | 2018 | 38 | 0.140 |
Why?
|
| Dose-Response Relationship, Radiation | 3 | 2012 | 36 | 0.140 |
Why?
|
| Genetic Markers | 1 | 2018 | 93 | 0.140 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2019 | 156 | 0.140 |
Why?
|
| B7-H1 Antigen | 1 | 2017 | 38 | 0.140 |
Why?
|
| Immunoblotting | 2 | 2015 | 124 | 0.140 |
Why?
|
| Digoxin | 1 | 2017 | 8 | 0.140 |
Why?
|
| Radiography | 3 | 2013 | 202 | 0.140 |
Why?
|
| Lactones | 1 | 2017 | 7 | 0.140 |
Why?
|
| Optical Imaging | 1 | 2018 | 34 | 0.140 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2022 | 127 | 0.140 |
Why?
|
| Tumor Hypoxia | 1 | 2017 | 2 | 0.140 |
Why?
|
| Epigenesis, Genetic | 1 | 2019 | 147 | 0.140 |
Why?
|
| Tubulin Modulators | 1 | 2017 | 17 | 0.140 |
Why?
|
| Taxoids | 1 | 2017 | 37 | 0.140 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2015 | 328 | 0.140 |
Why?
|
| Random Allocation | 1 | 2017 | 151 | 0.140 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 2 | 2007 | 19 | 0.140 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2015 | 247 | 0.140 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2018 | 109 | 0.140 |
Why?
|
| Oncogenes | 1 | 2017 | 34 | 0.140 |
Why?
|
| Breast Neoplasms | 1 | 2022 | 459 | 0.130 |
Why?
|
| Amino Acid Transport Systems, Neutral | 1 | 2016 | 2 | 0.130 |
Why?
|
| Flow Cytometry | 1 | 2018 | 288 | 0.130 |
Why?
|
| Microtubules | 1 | 2017 | 90 | 0.130 |
Why?
|
| Citric Acid Cycle | 2 | 2017 | 15 | 0.130 |
Why?
|
| Nitrogen | 1 | 2017 | 78 | 0.130 |
Why?
|
| Models, Molecular | 3 | 2014 | 452 | 0.130 |
Why?
|
| AMP-Activated Protein Kinases | 2 | 2019 | 43 | 0.130 |
Why?
|
| Up-Regulation | 4 | 2022 | 246 | 0.130 |
Why?
|
| Tryptophan | 1 | 2016 | 39 | 0.130 |
Why?
|
| Carbon | 1 | 2017 | 108 | 0.130 |
Why?
|
| Hydrocephalus | 2 | 2013 | 52 | 0.130 |
Why?
|
| Limit of Detection | 1 | 2016 | 25 | 0.130 |
Why?
|
| Combined Modality Therapy | 3 | 2020 | 300 | 0.130 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 1 | 2016 | 46 | 0.130 |
Why?
|
| Hep G2 Cells | 2 | 2021 | 31 | 0.130 |
Why?
|
| Encephalocele | 2 | 2013 | 4 | 0.130 |
Why?
|
| Micelles | 1 | 2015 | 19 | 0.130 |
Why?
|
| Receptors, Lysophosphatidic Acid | 1 | 2015 | 12 | 0.120 |
Why?
|
| Antibodies, Monoclonal | 1 | 2017 | 329 | 0.120 |
Why?
|
| Brain | 2 | 2013 | 741 | 0.120 |
Why?
|
| Blood Flow Velocity | 3 | 2010 | 64 | 0.120 |
Why?
|
| Inclusion Bodies | 2 | 2012 | 7 | 0.120 |
Why?
|
| Genome, Bacterial | 2 | 2012 | 70 | 0.120 |
Why?
|
| Biomarkers | 1 | 2018 | 765 | 0.120 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 2 | 2012 | 5 | 0.120 |
Why?
|
| Liver | 2 | 2009 | 440 | 0.120 |
Why?
|
| In Situ Nick-End Labeling | 2 | 2012 | 43 | 0.120 |
Why?
|
| Drug Carriers | 1 | 2015 | 115 | 0.120 |
Why?
|
| Proteome | 2 | 2012 | 77 | 0.120 |
Why?
|
| Cluster Analysis | 2 | 2012 | 125 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2015 | 155 | 0.110 |
Why?
|
| Gene Expression Regulation | 1 | 2018 | 632 | 0.110 |
Why?
|
| HSP40 Heat-Shock Proteins | 1 | 2014 | 3 | 0.110 |
Why?
|
| Child, Preschool | 6 | 2013 | 1146 | 0.110 |
Why?
|
| Vision, Low | 1 | 2014 | 4 | 0.110 |
Why?
|
| HIV Integrase Inhibitors | 1 | 2013 | 2 | 0.110 |
Why?
|
| Pancreatitis | 2 | 2020 | 36 | 0.110 |
Why?
|
| Benzoquinones | 1 | 2013 | 26 | 0.110 |
Why?
|
| Lactams, Macrocyclic | 1 | 2013 | 26 | 0.110 |
Why?
|
| Myelitis | 1 | 2013 | 3 | 0.110 |
Why?
|
| Hematoma, Subdural, Chronic | 1 | 2013 | 7 | 0.110 |
Why?
|
| Hematoma, Epidural, Spinal | 1 | 2013 | 9 | 0.110 |
Why?
|
| Brain Stem | 1 | 2013 | 23 | 0.110 |
Why?
|
| Intracranial Hemorrhages | 1 | 2013 | 30 | 0.110 |
Why?
|
| Cerebral Arteries | 2 | 2010 | 33 | 0.110 |
Why?
|
| Cricetinae | 2 | 2011 | 129 | 0.110 |
Why?
|
| Calcinosis | 1 | 2013 | 25 | 0.100 |
Why?
|
| Cerebral Ventricle Neoplasms | 1 | 2013 | 7 | 0.100 |
Why?
|
| Vitamin E | 1 | 2013 | 11 | 0.100 |
Why?
|
| Third Ventricle | 1 | 2013 | 9 | 0.100 |
Why?
|
| Arthritis, Experimental | 1 | 2013 | 6 | 0.100 |
Why?
|
| Immunohistochemistry | 4 | 2019 | 463 | 0.100 |
Why?
|
| Nanoparticles | 1 | 2017 | 287 | 0.100 |
Why?
|
| Hydroxamic Acids | 1 | 2013 | 18 | 0.100 |
Why?
|
| Risk Factors | 2 | 2017 | 2081 | 0.100 |
Why?
|
| Neurosurgical Procedures | 2 | 2013 | 220 | 0.100 |
Why?
|
| Tuberculosis, Spinal | 1 | 2013 | 4 | 0.100 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2013 | 13 | 0.100 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2013 | 26 | 0.100 |
Why?
|
| Astrocytoma | 1 | 2013 | 35 | 0.100 |
Why?
|
| Chemistry, Physical | 1 | 2012 | 13 | 0.100 |
Why?
|
| Sirolimus | 1 | 2013 | 76 | 0.100 |
Why?
|
| Frontal Lobe | 1 | 2013 | 42 | 0.100 |
Why?
|
| Antitubercular Agents | 1 | 2013 | 16 | 0.100 |
Why?
|
| Endoribonucleases | 1 | 2012 | 10 | 0.100 |
Why?
|
| Early Medical Intervention | 1 | 2012 | 7 | 0.100 |
Why?
|
| Cyanobacteria | 1 | 2012 | 18 | 0.100 |
Why?
|
| Carpal Tunnel Syndrome | 1 | 2012 | 6 | 0.100 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2017 | 27 | 0.100 |
Why?
|
| Pediatrics | 1 | 2013 | 92 | 0.100 |
Why?
|
| p300-CBP Transcription Factors | 1 | 2012 | 14 | 0.100 |
Why?
|
| Lethal Dose 50 | 2 | 2012 | 13 | 0.100 |
Why?
|
| Crowdsourcing | 1 | 2012 | 4 | 0.100 |
Why?
|
| Antirheumatic Agents | 1 | 2013 | 57 | 0.100 |
Why?
|
| Ketoglutaric Acids | 1 | 2012 | 16 | 0.100 |
Why?
|
| Choristoma | 1 | 2012 | 6 | 0.100 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2013 | 55 | 0.100 |
Why?
|
| Meningomyelocele | 1 | 2012 | 12 | 0.100 |
Why?
|
| Antibodies | 1 | 2013 | 124 | 0.100 |
Why?
|
| Unilamellar Liposomes | 1 | 2012 | 4 | 0.100 |
Why?
|
| Chromans | 1 | 2013 | 59 | 0.100 |
Why?
|
| Immunosuppressive Agents | 1 | 2013 | 148 | 0.100 |
Why?
|
| Postoperative Complications | 3 | 2013 | 611 | 0.100 |
Why?
|
| Fractures, Malunited | 1 | 2012 | 1 | 0.100 |
Why?
|
| Annona | 1 | 2012 | 1 | 0.100 |
Why?
|
| Orthotic Devices | 1 | 2012 | 7 | 0.100 |
Why?
|
| Genome-Wide Association Study | 2 | 2010 | 234 | 0.100 |
Why?
|
| Food Storage | 1 | 2012 | 3 | 0.100 |
Why?
|
| Protein Structure, Tertiary | 2 | 2014 | 284 | 0.100 |
Why?
|
| Immobilization | 1 | 2012 | 15 | 0.100 |
Why?
|
| Indoles | 1 | 2013 | 99 | 0.100 |
Why?
|
| Transcription, Genetic | 3 | 2021 | 403 | 0.100 |
Why?
|
| Phytotherapy | 1 | 2012 | 22 | 0.100 |
Why?
|
| Endoscopy | 1 | 2012 | 56 | 0.100 |
Why?
|
| HSP70 Heat-Shock Proteins | 2 | 2009 | 43 | 0.100 |
Why?
|
| Odontoid Process | 1 | 2012 | 12 | 0.100 |
Why?
|
| Toll-Like Receptor 6 | 1 | 2011 | 1 | 0.100 |
Why?
|
| Mycoplasma | 1 | 2011 | 2 | 0.100 |
Why?
|
| Pancytopenia | 1 | 2011 | 2 | 0.100 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2012 | 31 | 0.100 |
Why?
|
| Blood Cells | 1 | 2012 | 10 | 0.100 |
Why?
|
| Trans-Activators | 1 | 2012 | 118 | 0.100 |
Why?
|
| Lipopeptides | 1 | 2011 | 4 | 0.100 |
Why?
|
| Crops, Agricultural | 1 | 2012 | 19 | 0.100 |
Why?
|
| Exome | 1 | 2012 | 30 | 0.100 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2012 | 49 | 0.100 |
Why?
|
| Unconsciousness | 1 | 2011 | 3 | 0.100 |
Why?
|
| Heterocyclic Compounds | 1 | 2012 | 15 | 0.100 |
Why?
|
| Stem Cells | 1 | 2013 | 121 | 0.090 |
Why?
|
| Thermodynamics | 1 | 2012 | 93 | 0.090 |
Why?
|
| Ultracentrifugation | 1 | 2011 | 8 | 0.090 |
Why?
|
| Intestines | 1 | 2013 | 118 | 0.090 |
Why?
|
| Toll-Like Receptor 2 | 1 | 2011 | 30 | 0.090 |
Why?
|
| Stromal Cells | 1 | 2012 | 61 | 0.090 |
Why?
|
| Scattering, Radiation | 1 | 2011 | 29 | 0.090 |
Why?
|
| Radiation Protection | 1 | 2011 | 17 | 0.090 |
Why?
|
| Genes, ras | 1 | 2011 | 12 | 0.090 |
Why?
|
| Spinal Fractures | 1 | 2012 | 41 | 0.090 |
Why?
|
| Computer Simulation | 2 | 2010 | 230 | 0.090 |
Why?
|
| Thoracic Outlet Syndrome | 1 | 2011 | 1 | 0.090 |
Why?
|
| Acromioclavicular Joint | 1 | 2011 | 2 | 0.090 |
Why?
|
| Cyclin-Dependent Kinase 5 | 1 | 2011 | 6 | 0.090 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2011 | 132 | 0.090 |
Why?
|
| Shoulder Pain | 1 | 2011 | 3 | 0.090 |
Why?
|
| Hedgehog Proteins | 2 | 2008 | 33 | 0.090 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2012 | 82 | 0.090 |
Why?
|
| DNA Primers | 1 | 2011 | 146 | 0.090 |
Why?
|
| Plants | 1 | 2012 | 68 | 0.090 |
Why?
|
| Radiation Dosage | 1 | 2011 | 54 | 0.090 |
Why?
|
| Diagnosis, Differential | 1 | 2012 | 371 | 0.090 |
Why?
|
| Lumbar Vertebrae | 1 | 2012 | 125 | 0.090 |
Why?
|
| Protein Isoforms | 2 | 2022 | 119 | 0.090 |
Why?
|
| Mesocricetus | 1 | 2011 | 11 | 0.090 |
Why?
|
| Binding Sites | 2 | 2014 | 353 | 0.090 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2013 | 163 | 0.090 |
Why?
|
| nef Gene Products, Human Immunodeficiency Virus | 1 | 2010 | 3 | 0.090 |
Why?
|
| Antiprotozoal Agents | 1 | 2011 | 7 | 0.090 |
Why?
|
| Catecholamines | 1 | 2010 | 18 | 0.090 |
Why?
|
| Crystallography, X-Ray | 1 | 2011 | 222 | 0.090 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2012 | 82 | 0.090 |
Why?
|
| Polymerase Chain Reaction | 1 | 2011 | 269 | 0.090 |
Why?
|
| Lymphatic Metastasis | 2 | 2012 | 125 | 0.090 |
Why?
|
| Drug Compounding | 1 | 2011 | 30 | 0.090 |
Why?
|
| Erythropoietin | 1 | 2010 | 12 | 0.090 |
Why?
|
| A549 Cells | 2 | 2021 | 17 | 0.090 |
Why?
|
| Operative Blood Salvage | 1 | 2010 | 3 | 0.090 |
Why?
|
| Fever | 1 | 2010 | 31 | 0.090 |
Why?
|
| Blood Transfusion, Autologous | 1 | 2010 | 9 | 0.090 |
Why?
|
| Connective Tissue Growth Factor | 1 | 2010 | 9 | 0.090 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2011 | 59 | 0.090 |
Why?
|
| Disease Outbreaks | 1 | 2010 | 53 | 0.090 |
Why?
|
| Calcium | 2 | 2022 | 235 | 0.090 |
Why?
|
| Hypopharynx | 1 | 2010 | 2 | 0.090 |
Why?
|
| Antineoplastic Agents | 2 | 2016 | 679 | 0.090 |
Why?
|
| Drug Design | 1 | 2011 | 63 | 0.090 |
Why?
|
| Neutropenia | 1 | 2010 | 41 | 0.090 |
Why?
|
| Base Sequence | 1 | 2011 | 584 | 0.090 |
Why?
|
| United States | 3 | 2021 | 2146 | 0.090 |
Why?
|
| Subcutaneous Emphysema | 1 | 2010 | 4 | 0.090 |
Why?
|
| Intervertebral Disc Displacement | 1 | 2010 | 10 | 0.090 |
Why?
|
| Sequence Analysis, DNA | 1 | 2012 | 369 | 0.090 |
Why?
|
| Anemia | 1 | 2010 | 43 | 0.090 |
Why?
|
| Arthroplasty, Replacement, Knee | 1 | 2010 | 38 | 0.080 |
Why?
|
| Cell Adhesion | 2 | 2007 | 138 | 0.080 |
Why?
|
| Cohort Studies | 4 | 2017 | 887 | 0.080 |
Why?
|
| Cerebral Hemorrhage | 1 | 2011 | 91 | 0.080 |
Why?
|
| Diskectomy | 1 | 2010 | 21 | 0.080 |
Why?
|
| Shear Strength | 1 | 2010 | 18 | 0.080 |
Why?
|
| Blood Viscosity | 1 | 2010 | 12 | 0.080 |
Why?
|
| Drug Delivery Systems | 1 | 2012 | 225 | 0.080 |
Why?
|
| Elective Surgical Procedures | 1 | 2010 | 70 | 0.080 |
Why?
|
| Podophyllotoxin | 1 | 2009 | 1 | 0.080 |
Why?
|
| Cyclin E | 1 | 2009 | 3 | 0.080 |
Why?
|
| Cyclin B1 | 1 | 2009 | 7 | 0.080 |
Why?
|
| Cyclin B | 1 | 2009 | 9 | 0.080 |
Why?
|
| Models, Biological | 1 | 2012 | 466 | 0.080 |
Why?
|
| Cyclin-Dependent Kinase 2 | 1 | 2009 | 7 | 0.080 |
Why?
|
| Basilar Artery | 1 | 2009 | 7 | 0.080 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2009 | 19 | 0.080 |
Why?
|
| CDC2 Protein Kinase | 1 | 2009 | 15 | 0.080 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2009 | 18 | 0.080 |
Why?
|
| Neurocysticercosis | 1 | 2009 | 13 | 0.080 |
Why?
|
| Heat Shock Transcription Factors | 1 | 2009 | 7 | 0.080 |
Why?
|
| ras GTPase-Activating Proteins | 1 | 2009 | 4 | 0.080 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2009 | 29 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2009 | 9 | 0.080 |
Why?
|
| DNA, Neoplasm | 1 | 2009 | 34 | 0.080 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2009 | 33 | 0.080 |
Why?
|
| Anticoagulants | 1 | 2011 | 294 | 0.080 |
Why?
|
| Blood Vessels | 1 | 2010 | 59 | 0.080 |
Why?
|
| Brain Stem Neoplasms | 1 | 2009 | 12 | 0.080 |
Why?
|
| Head and Neck Neoplasms | 1 | 2010 | 87 | 0.080 |
Why?
|
| Carotid Arteries | 1 | 2009 | 54 | 0.080 |
Why?
|
| Drug Interactions | 1 | 2009 | 79 | 0.080 |
Why?
|
| DNA, Mitochondrial | 2 | 2019 | 82 | 0.080 |
Why?
|
| Pilot Projects | 1 | 2011 | 433 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2009 | 68 | 0.080 |
Why?
|
| Hyperplasia | 2 | 2022 | 27 | 0.080 |
Why?
|
| Pattern Recognition, Automated | 1 | 2009 | 32 | 0.080 |
Why?
|
| Protein Folding | 1 | 2008 | 47 | 0.080 |
Why?
|
| Image Enhancement | 1 | 2009 | 58 | 0.080 |
Why?
|
| Ubiquitin | 1 | 2008 | 24 | 0.080 |
Why?
|
| Microsurgery | 1 | 2009 | 45 | 0.080 |
Why?
|
| Radiotherapy | 1 | 2009 | 41 | 0.080 |
Why?
|
| HIV Infections | 1 | 2010 | 159 | 0.080 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2008 | 17 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2008 | 12 | 0.080 |
Why?
|
| Transcription Factor AP-1 | 1 | 2008 | 26 | 0.070 |
Why?
|
| Artificial Intelligence | 1 | 2009 | 53 | 0.070 |
Why?
|
| Spinal Fusion | 1 | 2011 | 146 | 0.070 |
Why?
|
| Cells, Cultured | 3 | 2020 | 985 | 0.070 |
Why?
|
| Berberidaceae | 1 | 2008 | 1 | 0.070 |
Why?
|
| Colony-Forming Units Assay | 1 | 2008 | 8 | 0.070 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2008 | 80 | 0.070 |
Why?
|
| Bacterial Proteins | 1 | 2012 | 485 | 0.070 |
Why?
|
| Receptor, ErbB-2 | 1 | 2008 | 33 | 0.070 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2009 | 107 | 0.070 |
Why?
|
| Drug Synergism | 2 | 2019 | 104 | 0.070 |
Why?
|
| Neurosurgery | 1 | 2009 | 75 | 0.070 |
Why?
|
| Myelin-Associated Glycoprotein | 1 | 2007 | 3 | 0.070 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2010 | 251 | 0.070 |
Why?
|
| Lectins | 1 | 2007 | 13 | 0.070 |
Why?
|
| Glioma | 1 | 2009 | 117 | 0.070 |
Why?
|
| Perineum | 1 | 2007 | 14 | 0.070 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2008 | 131 | 0.070 |
Why?
|
| Drug Therapy, Combination | 1 | 2008 | 207 | 0.070 |
Why?
|
| Down-Regulation | 3 | 2018 | 199 | 0.070 |
Why?
|
| Pancreatic Ducts | 1 | 2007 | 10 | 0.070 |
Why?
|
| Amino Acid Motifs | 1 | 2007 | 66 | 0.070 |
Why?
|
| Morbidity | 1 | 2007 | 58 | 0.070 |
Why?
|
| Peptides | 2 | 2022 | 288 | 0.070 |
Why?
|
| Heterografts | 2 | 2018 | 66 | 0.070 |
Why?
|
| Tyrosine | 1 | 2007 | 92 | 0.070 |
Why?
|
| Anti-Bacterial Agents | 1 | 2011 | 523 | 0.070 |
Why?
|
| Global Health | 1 | 2007 | 51 | 0.070 |
Why?
|
| Ultrasonography, Interventional | 1 | 2007 | 39 | 0.070 |
Why?
|
| beta Catenin | 1 | 2007 | 66 | 0.070 |
Why?
|
| Host-Pathogen Interactions | 2 | 2021 | 91 | 0.070 |
Why?
|
| Biopsy | 1 | 2007 | 206 | 0.060 |
Why?
|
| DNA | 2 | 2022 | 374 | 0.060 |
Why?
|
| Cross-Over Studies | 1 | 2006 | 134 | 0.060 |
Why?
|
| Bone Marrow | 2 | 2020 | 76 | 0.060 |
Why?
|
| Stents | 1 | 2007 | 120 | 0.060 |
Why?
|
| Radiopharmaceuticals | 1 | 2006 | 71 | 0.060 |
Why?
|
| Proportional Hazards Models | 1 | 2006 | 226 | 0.060 |
Why?
|
| Mass Spectrometry | 1 | 2007 | 190 | 0.060 |
Why?
|
| Case-Control Studies | 2 | 2022 | 722 | 0.060 |
Why?
|
| Receptors, Cell Surface | 1 | 2006 | 114 | 0.060 |
Why?
|
| Fibroblasts | 2 | 2022 | 157 | 0.060 |
Why?
|
| DNA-Binding Proteins | 1 | 2009 | 490 | 0.060 |
Why?
|
| Phenotype | 3 | 2017 | 680 | 0.060 |
Why?
|
| Recombinant Proteins | 3 | 2012 | 413 | 0.060 |
Why?
|
| Chronic Disease | 1 | 2006 | 271 | 0.060 |
Why?
|
| Epithelial Cells | 1 | 2006 | 248 | 0.060 |
Why?
|
| Lung | 2 | 2018 | 379 | 0.060 |
Why?
|
| Follow-Up Studies | 3 | 2013 | 1013 | 0.060 |
Why?
|
| Retrospective Studies | 4 | 2013 | 2546 | 0.050 |
Why?
|
| HeLa Cells | 2 | 2015 | 208 | 0.050 |
Why?
|
| Seizures | 2 | 2013 | 48 | 0.050 |
Why?
|
| Structure-Activity Relationship | 2 | 2014 | 208 | 0.050 |
Why?
|
| Neurologic Examination | 2 | 2013 | 21 | 0.050 |
Why?
|
| Jejunum | 2 | 2013 | 8 | 0.050 |
Why?
|
| Protein Interaction Mapping | 2 | 2012 | 34 | 0.050 |
Why?
|
| Cystine | 1 | 2022 | 6 | 0.050 |
Why?
|
| Kelch-Like ECH-Associated Protein 1 | 1 | 2022 | 15 | 0.050 |
Why?
|
| Mammary Glands, Animal | 1 | 2022 | 33 | 0.050 |
Why?
|
| Precancerous Conditions | 1 | 2022 | 37 | 0.050 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2022 | 48 | 0.050 |
Why?
|
| Guinea Pigs | 1 | 2022 | 73 | 0.050 |
Why?
|
| Endonucleases | 1 | 2022 | 17 | 0.050 |
Why?
|
| Fatal Outcome | 2 | 2013 | 67 | 0.050 |
Why?
|
| Uncoupling Protein 1 | 1 | 2022 | 14 | 0.050 |
Why?
|
| Atrophy | 1 | 2022 | 15 | 0.050 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2022 | 115 | 0.050 |
Why?
|
| Gastric Acid | 1 | 2021 | 19 | 0.050 |
Why?
|
| NAD | 1 | 2022 | 100 | 0.050 |
Why?
|
| Proton Pump Inhibitors | 1 | 2021 | 27 | 0.050 |
Why?
|
| Mammals | 1 | 2022 | 48 | 0.050 |
Why?
|
| Mitosis | 1 | 2022 | 112 | 0.050 |
Why?
|
| Filgrastim | 2 | 2012 | 7 | 0.050 |
Why?
|
| United States Food and Drug Administration | 1 | 2021 | 44 | 0.050 |
Why?
|
| Paclitaxel | 1 | 2022 | 190 | 0.050 |
Why?
|
| Autophagy-Related Proteins | 1 | 2021 | 9 | 0.040 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2022 | 122 | 0.040 |
Why?
|
| Acetyl Coenzyme A | 1 | 2021 | 18 | 0.040 |
Why?
|
| Acetylation | 1 | 2021 | 37 | 0.040 |
Why?
|
| Analysis of Variance | 2 | 2013 | 391 | 0.040 |
Why?
|
| NADPH Oxidases | 1 | 2021 | 69 | 0.040 |
Why?
|
| Fatty Acids | 1 | 2022 | 206 | 0.040 |
Why?
|
| Octamer Transcription Factors | 1 | 2020 | 1 | 0.040 |
Why?
|
| Ceruletide | 1 | 2020 | 7 | 0.040 |
Why?
|
| Intramolecular Oxidoreductases | 1 | 2020 | 8 | 0.040 |
Why?
|
| Neoplasm Staging | 1 | 2022 | 478 | 0.040 |
Why?
|
| Leucovorin | 1 | 2020 | 19 | 0.040 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2020 | 25 | 0.040 |
Why?
|
| Transplantation, Autologous | 1 | 2020 | 42 | 0.040 |
Why?
|
| Fluorouracil | 1 | 2020 | 58 | 0.040 |
Why?
|
| Cancer Vaccines | 1 | 2020 | 33 | 0.040 |
Why?
|
| Splenectomy | 1 | 2020 | 44 | 0.040 |
Why?
|
| Adaptive Immunity | 1 | 2020 | 38 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2020 | 113 | 0.040 |
Why?
|
| Lymph Node Excision | 1 | 2020 | 100 | 0.040 |
Why?
|
| Pancreatectomy | 1 | 2020 | 58 | 0.040 |
Why?
|
| Neoadjuvant Therapy | 1 | 2020 | 73 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2020 | 237 | 0.040 |
Why?
|
| Lymph Nodes | 1 | 2020 | 103 | 0.040 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2020 | 42 | 0.040 |
Why?
|
| Hemoglobins | 2 | 2010 | 118 | 0.040 |
Why?
|
| Gene Expression | 2 | 2012 | 417 | 0.040 |
Why?
|
| Gene Knockout Techniques | 1 | 2019 | 35 | 0.040 |
Why?
|
| Transplantation, Heterologous | 1 | 2019 | 60 | 0.040 |
Why?
|
| Protein Transport | 1 | 2020 | 158 | 0.040 |
Why?
|
| Activating Transcription Factor 6 | 1 | 2019 | 4 | 0.040 |
Why?
|
| Cell Communication | 1 | 2020 | 68 | 0.040 |
Why?
|
| Infant, Newborn | 2 | 2013 | 885 | 0.040 |
Why?
|
| Bortezomib | 1 | 2019 | 22 | 0.040 |
Why?
|
| Age Factors | 2 | 2013 | 734 | 0.040 |
Why?
|
| Interleukins | 1 | 2020 | 112 | 0.040 |
Why?
|
| Neoplasms, Experimental | 2 | 2012 | 58 | 0.040 |
Why?
|
| Threonine | 1 | 2019 | 21 | 0.040 |
Why?
|
| THP-1 Cells | 1 | 2018 | 2 | 0.040 |
Why?
|
| Hexosamines | 1 | 2018 | 2 | 0.040 |
Why?
|
| Serine | 1 | 2019 | 51 | 0.040 |
Why?
|
| Vero Cells | 1 | 2018 | 12 | 0.040 |
Why?
|
| HT29 Cells | 1 | 2018 | 20 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2020 | 214 | 0.040 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2019 | 135 | 0.040 |
Why?
|
| Fibrosarcoma | 1 | 2018 | 12 | 0.040 |
Why?
|
| Superoxide Dismutase | 1 | 2019 | 71 | 0.040 |
Why?
|
| Hemorrhage | 2 | 2011 | 265 | 0.040 |
Why?
|
| Oligopeptides | 1 | 2019 | 97 | 0.040 |
Why?
|
| T-Lymphocytes | 1 | 2020 | 282 | 0.040 |
Why?
|
| Isoenzymes | 1 | 2018 | 86 | 0.040 |
Why?
|
| Hydrogen Peroxide | 1 | 2019 | 144 | 0.040 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 2019 | 112 | 0.040 |
Why?
|
| Bleomycin | 1 | 2018 | 11 | 0.040 |
Why?
|
| Lymphocyte Activation | 1 | 2019 | 209 | 0.040 |
Why?
|
| Immunity, Cellular | 1 | 2017 | 23 | 0.040 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2017 | 28 | 0.040 |
Why?
|
| Myofibroblasts | 1 | 2018 | 23 | 0.040 |
Why?
|
| DNA Methylation | 1 | 2019 | 152 | 0.030 |
Why?
|
| Deoxyglucose | 1 | 2017 | 9 | 0.030 |
Why?
|
| Aspartic Acid | 1 | 2017 | 52 | 0.030 |
Why?
|
| Hydroxybenzoates | 1 | 2017 | 6 | 0.030 |
Why?
|
| Drug Resistance, Multiple | 1 | 2017 | 20 | 0.030 |
Why?
|
| DNA Replication | 1 | 2017 | 51 | 0.030 |
Why?
|
| Amino Acid Transport Systems | 1 | 2016 | 2 | 0.030 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2017 | 180 | 0.030 |
Why?
|
| Polyesters | 1 | 2015 | 35 | 0.030 |
Why?
|
| Polyethylene Glycols | 1 | 2015 | 101 | 0.030 |
Why?
|
| Polymers | 1 | 2015 | 117 | 0.030 |
Why?
|
| Subcutaneous Tissue | 1 | 2013 | 3 | 0.030 |
Why?
|
| Tomography Scanners, X-Ray Computed | 1 | 2013 | 3 | 0.030 |
Why?
|
| Cranial Nerve Diseases | 1 | 2013 | 10 | 0.030 |
Why?
|
| Glasgow Outcome Scale | 1 | 2013 | 3 | 0.030 |
Why?
|
| HIV Integrase | 1 | 2013 | 1 | 0.030 |
Why?
|
| Autopsy | 1 | 2013 | 25 | 0.030 |
Why?
|
| Skull Base | 1 | 2014 | 34 | 0.030 |
Why?
|
| Cytochrome P-450 Enzyme Inhibitors | 1 | 2013 | 3 | 0.030 |
Why?
|
| Cerebral Angiography | 1 | 2013 | 38 | 0.030 |
Why?
|
| Headache | 1 | 2013 | 34 | 0.030 |
Why?
|
| Rupture, Spontaneous | 1 | 2013 | 10 | 0.030 |
Why?
|
| Glucuronosyltransferase | 1 | 2013 | 29 | 0.030 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2013 | 33 | 0.030 |
Why?
|
| Survivors | 1 | 2013 | 40 | 0.030 |
Why?
|
| Ligands | 1 | 2014 | 176 | 0.030 |
Why?
|
| Freund's Adjuvant | 1 | 2013 | 8 | 0.030 |
Why?
|
| Histone Deacetylase 6 | 1 | 2013 | 4 | 0.030 |
Why?
|
| Mice, Inbred DBA | 1 | 2013 | 30 | 0.030 |
Why?
|
| DNA Breaks | 1 | 2013 | 2 | 0.030 |
Why?
|
| Paraplegia | 1 | 2013 | 3 | 0.030 |
Why?
|
| Case Management | 1 | 2013 | 11 | 0.030 |
Why?
|
| Endotoxins | 1 | 2013 | 28 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2013 | 104 | 0.030 |
Why?
|
| Urinary Bladder Diseases | 1 | 2013 | 9 | 0.030 |
Why?
|
| Urine | 1 | 2013 | 14 | 0.030 |
Why?
|
| Synechocystis | 1 | 2012 | 3 | 0.030 |
Why?
|
| Databases, Protein | 1 | 2012 | 22 | 0.030 |
Why?
|
| Rats, Wistar | 1 | 2013 | 151 | 0.030 |
Why?
|
| RNA Processing, Post-Transcriptional | 1 | 2012 | 20 | 0.030 |
Why?
|
| Spinal Cord Compression | 1 | 2013 | 20 | 0.030 |
Why?
|
| Sequence Analysis, Protein | 1 | 2012 | 15 | 0.030 |
Why?
|
| Craniotomy | 1 | 2013 | 61 | 0.030 |
Why?
|
| Molecular Structure | 1 | 2013 | 243 | 0.030 |
Why?
|
| Nervous System Diseases | 1 | 2013 | 40 | 0.030 |
Why?
|
| RNA Stability | 1 | 2012 | 28 | 0.030 |
Why?
|
| Ubiquitination | 1 | 2012 | 32 | 0.030 |
Why?
|
| Waiting Lists | 1 | 2012 | 10 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2013 | 95 | 0.030 |
Why?
|
| Antibodies, Neutralizing | 1 | 2013 | 72 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2013 | 145 | 0.030 |
Why?
|
| Molecular Weight | 1 | 2012 | 119 | 0.020 |
Why?
|
| Tissue Array Analysis | 1 | 2012 | 24 | 0.020 |
Why?
|
| Protein Structure, Secondary | 1 | 2012 | 130 | 0.020 |
Why?
|
| ROC Curve | 1 | 2013 | 144 | 0.020 |
Why?
|
| Plasmids | 1 | 2012 | 126 | 0.020 |
Why?
|
| User-Computer Interface | 1 | 2012 | 52 | 0.020 |
Why?
|
| Amino Acids | 1 | 2012 | 84 | 0.020 |
Why?
|
| Equipment Failure Analysis | 1 | 2012 | 37 | 0.020 |
Why?
|
| Radiation Chimera | 1 | 2012 | 5 | 0.020 |
Why?
|
| Spine | 1 | 2013 | 61 | 0.020 |
Why?
|
| Nitric Oxide | 1 | 2013 | 152 | 0.020 |
Why?
|
| Benzylamines | 1 | 2012 | 19 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2012 | 168 | 0.020 |
Why?
|
| Glucose Transporter Type 4 | 1 | 2012 | 62 | 0.020 |
Why?
|
| Crosses, Genetic | 1 | 2012 | 36 | 0.020 |
Why?
|
| Multiprotein Complexes | 1 | 2012 | 54 | 0.020 |
Why?
|
| Prosthesis Design | 1 | 2012 | 87 | 0.020 |
Why?
|
| Patient Satisfaction | 1 | 2012 | 96 | 0.020 |
Why?
|
| Plant Physiological Phenomena | 1 | 2012 | 19 | 0.020 |
Why?
|
| Microscopy, Confocal | 1 | 2012 | 113 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2011 | 58 | 0.020 |
Why?
|
| Internet | 1 | 2012 | 124 | 0.020 |
Why?
|
| Purines | 1 | 2011 | 16 | 0.020 |
Why?
|
| Brachial Plexus | 1 | 2011 | 6 | 0.020 |
Why?
|
| Gene Amplification | 1 | 2011 | 22 | 0.020 |
Why?
|
| Clavicle | 1 | 2011 | 5 | 0.020 |
Why?
|
| Scapula | 1 | 2011 | 11 | 0.020 |
Why?
|
| Genomics | 1 | 2012 | 123 | 0.020 |
Why?
|
| Osteotomy | 1 | 2011 | 24 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2011 | 224 | 0.020 |
Why?
|
| RGS Proteins | 1 | 2010 | 5 | 0.020 |
Why?
|
| Aedes | 1 | 2010 | 5 | 0.020 |
Why?
|
| Lipodystrophy | 1 | 2010 | 6 | 0.020 |
Why?
|
| Receptors, Adrenergic, beta | 1 | 2010 | 24 | 0.020 |
Why?
|
| Mexican Americans | 1 | 2010 | 13 | 0.020 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2010 | 25 | 0.020 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2010 | 22 | 0.020 |
Why?
|
| Body Temperature | 1 | 2010 | 30 | 0.020 |
Why?
|
| Oxazines | 1 | 2010 | 19 | 0.020 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2010 | 29 | 0.020 |
Why?
|
| Caenorhabditis elegans | 1 | 2010 | 58 | 0.020 |
Why?
|
| Dietary Fats | 1 | 2010 | 59 | 0.020 |
Why?
|
| Cyclic AMP | 1 | 2010 | 87 | 0.020 |
Why?
|
| India | 1 | 2010 | 142 | 0.020 |
Why?
|
| Drainage | 1 | 2010 | 45 | 0.020 |
Why?
|
| Surgical Instruments | 1 | 2010 | 15 | 0.020 |
Why?
|
| Models, Animal | 1 | 2011 | 129 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2012 | 514 | 0.020 |
Why?
|
| Respiratory Insufficiency | 1 | 2010 | 14 | 0.020 |
Why?
|
| Intestinal Mucosa | 1 | 2012 | 197 | 0.020 |
Why?
|
| Japan | 1 | 2010 | 23 | 0.020 |
Why?
|
| Iatrogenic Disease | 1 | 2010 | 14 | 0.020 |
Why?
|
| Nerve Tissue Proteins | 1 | 2011 | 153 | 0.020 |
Why?
|
| Prostheses and Implants | 1 | 2010 | 28 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2013 | 330 | 0.020 |
Why?
|
| Bacteria | 1 | 2013 | 281 | 0.020 |
Why?
|
| Trachea | 1 | 2010 | 26 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2013 | 961 | 0.020 |
Why?
|
| Europe | 1 | 2010 | 98 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2010 | 194 | 0.020 |
Why?
|
| Models, Genetic | 1 | 2010 | 125 | 0.020 |
Why?
|
| Escherichia coli | 1 | 2012 | 337 | 0.020 |
Why?
|
| Temperature | 1 | 2010 | 213 | 0.020 |
Why?
|
| Carotid Artery, Common | 1 | 2009 | 10 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2010 | 236 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2010 | 161 | 0.020 |
Why?
|
| Extracellular Matrix | 1 | 2010 | 117 | 0.020 |
Why?
|
| Models, Neurological | 1 | 2009 | 32 | 0.020 |
Why?
|
| Iron | 1 | 2010 | 116 | 0.020 |
Why?
|
| Insulin Resistance | 1 | 2010 | 175 | 0.020 |
Why?
|
| Stress, Mechanical | 1 | 2009 | 115 | 0.020 |
Why?
|
| Genotype | 1 | 2010 | 456 | 0.020 |
Why?
|
| Cell Line, Transformed | 1 | 2008 | 42 | 0.020 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2009 | 129 | 0.020 |
Why?
|
| Phantoms, Imaging | 1 | 2009 | 100 | 0.020 |
Why?
|
| Hemodynamics | 1 | 2009 | 220 | 0.020 |
Why?
|
| Mucin-4 | 1 | 2008 | 2 | 0.020 |
Why?
|
| Blood Pressure | 1 | 2009 | 354 | 0.020 |
Why?
|
| Sialic Acid Binding Immunoglobulin-like Lectins | 1 | 2007 | 1 | 0.020 |
Why?
|
| Schwann Cells | 1 | 2007 | 4 | 0.020 |
Why?
|
| Cricetulus | 1 | 2007 | 56 | 0.020 |
Why?
|
| CHO Cells | 1 | 2007 | 96 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2007 | 68 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2010 | 547 | 0.020 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2007 | 32 | 0.020 |
Why?
|
| Receptors, Notch | 1 | 2007 | 45 | 0.020 |
Why?
|
| Sphincter of Oddi Dysfunction | 1 | 2007 | 1 | 0.020 |
Why?
|
| Monte Carlo Method | 1 | 2007 | 62 | 0.020 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2007 | 122 | 0.020 |
Why?
|
| Protein Binding | 1 | 2008 | 658 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2007 | 112 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2009 | 769 | 0.020 |
Why?
|
| Quality of Life | 1 | 2010 | 487 | 0.020 |
Why?
|
| Decision Making | 1 | 2007 | 175 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2007 | 452 | 0.010 |
Why?
|
| Obesity | 1 | 2010 | 669 | 0.010 |
Why?
|